ATYR · aTYR PHARMA INC
$0.52
-0.04 (-6.64%)
At close · Aug 17
Market Cap
$54.83M
Shares
98.09M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.56
Open$0.56
Day$0.55–0.59
52W close$0.40–6.03
Avg vol 30d1.1M
Short int9.7M · 9.9% float · 11.8d
Short vol26%
Last earningsMar 13, 2025
DataJan 2020–Aug 2026
Filing10-Q · Aug 7
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 7, 2026
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Neutral
Momentum
Weak
Sentiment
Neutral
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 14.3 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−22%
below
Price vs 50-day avg
+8%
above
RSI (14)
59
neutral
MACD trend
Positive
52-week position
3%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+10%
trailing
6-month return
−45%
trailing
YTD return
−29%
this year
Relative strength
−58%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow
Distributing
-18% holders QoQ · +17 funds added
Insider flow
Accumulating
Net +$49.6K over 90 days · 0% sells
Short interest
Rising
9.92% of float · ▲ +17.5% MoM · 11.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
93 holders — mid 3-yr range
Squeeze score
86
high risk · 0–100
Fundamentals
Revenue growth
−19%
Y/Y
EPS growth
+7%
Y/Y
Free cash flow
$-62.1M
Balance sheet
$6.3M
net debt
Quant / Vol
risk profile
Volatility
137%
annualized · 1-yr
Max drawdown
−93%
past year
ATR
7.1%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Aug 7, 2026
Annualized operating expenses reduction
· fourth quarter of 2026
$13M
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−22%
Bearish
Price vs 50-day avg
+8%
Bullish
RSI (14)
59
Neutral
MACD trend
Positive
Bullish
52-week position
3%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow
Distributing
-18% holders QoQ · +17 funds added
Insider flow
Accumulating
Net +$49.6K over 90 days · 0% sells
Short interest
Rising
9.92% of float · ▲ +17.5% MoM · 11.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
93 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $0
Now $1 · 3%
Range high $6
vs 200-day avg -22%
vs 50-day avg +8%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ATYR
this stock
aTYR PHARMA INC
|
$54.83M | -28.6% | -19.1% | — | 9.9% |
|
ONC
BeOne Medicines Ltd.
|
$513.62B | +14.4% | +22179.2% | 789.7 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$128.19B | +11.6% | +46.2% | 29.5 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$82.72B | +4.1% | +20.8% | 19.9 | 3.3% |
|
ARGX
Argenx SE
|
$52.94B | +1.2% | — | — | 2.1% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ATYR | +9.4% | +9.6% | -44.7% | +15.0% | -28.6% |
| SPY | +0.4% | +4.5% | +13.8% | +3.9% | +13.9% |
| vs SPY | +9.0% | +5.2% | -58.4% | +11.1% | -42.5% |
Key facts
CIK
1339970
CUSIP
002120202
13F (30d)
87 filings
85 filers
Visit website
Investor relations